One drug isnt better than the other, but semaglutide (the active ingredient in Wegovy and Ozempic) targets a single potent pathway (the GLP-1 receptor), while retatrutide is a triple-agonist, acting on GLP-1, GIP, and glucagon receptors
Aceasta reduce riscul de mortalitate cu 27%, a aritmiilor ventriculare cu 65% si a anginei cu 40% pe termen scurt
Whilst Januvia modestly enhances the body's own incretin response, Mounjaro delivers a powerful, direct receptor activation that produces greater reductions in HbA1c and body weight, as demonstrated in clinical trials and documented in the EMA's European Public Assessment Report (EPAR)
It begins with the coagulation cascade, which promotes the release of thrombomodulin from vascular cells
doi: 10.1186/s13046-024-03235-0